H. Robert Superko/a4m.com
Aug 11, 2025, 06:08
New Data From WHS and ASPREE: Aspirin Heart Disease Prevention Conundrum
Maxima Mendez, Cardiologist, CEO of Cli-Lipid and the Cardiovascular Lipid Club, shared a post on X:
“New data from WHS and ASPREE:
Aspirin and Lpa
•LPA+ genotype → higher CVD risk, aspirin reduced events significantly (NNT: 38–34)
•LPA– genotype → normal CVD risk, bleeding risk outweighs benefit (NNT: 833–250)”
Read the full article here.
Article: The aspirin heart disease prevention conundrum
Authors: H. Robert Superko, John Sninsky, Brenda Garrett․
Stay updated with Hemostasis Today.
-
Oct 13, 2026, 12:29Mariam Al Mansoori: 5th International Hemophilia Conference
-
Oct 13, 2026, 12:13Hemophilia Outreach of Wisconsin Attends VWD Connect Conference
-
Oct 13, 2026, 11:41Abhishek Kumar: How Three Hemophilia Patients Helped Secure Life-Saving Treatment in Bihar
-
Oct 13, 2026, 11:24Brandon Daniel D’Costa: Building Stronger Stakeholder Relationships Through Empathy and Open Communication
-
Oct 13, 2026, 11:08Renel Tique: 5th International Conference on Hemophilia and Rare Bleeding Disorders
-
Oct 13, 2026, 02:01Nour Al-Mozain: Is It Really Anti-D? – Unraveling Auto-Anti-LW in the Transfusion Laboratory
-
Oct 13, 2026, 01:51Berenice Villegas: The Role of Morphologic Evaluation in Body Fluid Differential Analysis
-
Oct 13, 2026, 01:44Debadrita Ray: Evaluating vWF and VITRO Score for Detecting CSPH in cACLD Patients
-
Oct 13, 2026, 01:34Nagesh Ramesh: Donating Blood for International Plasma Awareness Week